AZN.UK

10,352

-1.48%↓

GSK

1,424.5

-0.52%↓

AZN.UK

10,352

-1.48%↓

GSK

1,424.5

-0.52%↓

AZN.UK

10,352

-1.48%↓

GSK

1,424.5

-0.52%↓

AZN.UK

10,352

-1.48%↓

GSK

1,424.5

-0.52%↓

AZN.UK

10,352

-1.48%↓

GSK

1,424.5

-0.52%↓

Search

Indivior PLC

Deschisă

829.5 -1.54

Rezumat

Modificarea prețului

24h

Curent

Minim

815

Maxim

841.5

Indicatori cheie

By Trading Economics

Venit

-19M

47M

Vânzări

-33M

266M

P/E

Medie Sector

330

54.533

EPS

0.41

Marjă de profit

17.669

Angajați

1,030

EBITDA

-30M

76M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+20.19% upside

Dividende

By Dow Jones

Următoarele câștiguri

24 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

259M

1.1B

Deschiderea anterioară

831.04

Închiderea anterioară

829.5

Indivior PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 mai 2025, 23:48 UTC

Acțiuni populare

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22 mai 2025, 23:07 UTC

Top știri

Fortescue Energy CEO to Resign in Executive Overhaul

22 mai 2025, 23:03 UTC

Principalele dinamici ale pieței

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22 mai 2025, 23:59 UTC

Market Talk

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22 mai 2025, 23:45 UTC

Market Talk

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22 mai 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

22 mai 2025, 23:23 UTC

Market Talk

Global Energy Roundup: Market Talk

22 mai 2025, 23:23 UTC

Market Talk

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22 mai 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 mai 2025, 20:46 UTC

Achiziții, Fuziuni, Preluări

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22 mai 2025, 20:39 UTC

Câștiguri

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22 mai 2025, 20:36 UTC

Top știri

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22 mai 2025, 20:36 UTC

Top știri
Câștiguri

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22 mai 2025, 20:32 UTC

Top știri
Câștiguri

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 mai 2025, 20:27 UTC

Top știri

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22 mai 2025, 20:20 UTC

Top știri

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 mai 2025, 20:17 UTC

Top știri

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22 mai 2025, 20:16 UTC

Câștiguri

Intchains Group 1Q Rev $18.2M >ICG

22 mai 2025, 20:15 UTC

Top știri

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 mai 2025, 20:08 UTC

Top știri
Câștiguri

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 mai 2025, 20:05 UTC

Top știri

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22 mai 2025, 20:04 UTC

Câștiguri

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22 mai 2025, 20:04 UTC

Câștiguri

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22 mai 2025, 20:01 UTC

Câștiguri

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22 mai 2025, 20:01 UTC

Câștiguri

Workday 1Q Net $68M >WDAY

22 mai 2025, 20:01 UTC

Câștiguri

Workday 1Q EPS 25c >WDAY

22 mai 2025, 20:01 UTC

Câștiguri

Workday 1Q Adj EPS $2.23 >WDAY

22 mai 2025, 20:01 UTC

Câștiguri

Workday 1Q Subscription Revenue $2.06B >WDAY

22 mai 2025, 20:01 UTC

Câștiguri

Workday 1Q Rev $2.24B >WDAY

Comparație

Modificare preț

Indivior PLC Așteptări

Obiectiv de preț

By TipRanks

20.19% sus

Prognoză pe 12 luni

Medie 1,014.42 GBX  20.19%

Maxim 1,100 GBX

Minim 968.247 GBX

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIndivior PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

4

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.